Find in Library

Oxime derivatives of dehydrocholic acid and its esters were designed for anti-hepatitis B virus (HBV) drugs according to principles of assembling active chemical fragments. Twelve compounds were synthesized from dehydrocholic acid by esterification and oxime formation, and their anti-hepatitis B virus (HBV) activities were evaluated with HepG 2.2.15 cells. Results showed that 5 compounds exhibited more effective inhibition of HBeAg than positive control, among them <b>2b-3</b> and <b>2b-1</b> showed significant anti-HBV activities on inhibiting secretion of HBeAg (IC_{50 (<b>2b-3</b>)} = 49.39 ± 12.78 μM, SI _{(<b>2b-3</b>)} = 11.03; IC_{50 (<b>2b-1</b>)} = 96.64 ± 28.99 μM, SI _{(<b>2b-1</b>)} = 10.35) compared to the Entecavir (IC₅₀ = 161.24 μM, SI = 3.72). Molecular docking studies showed that most of these compounds interacted with protein residues of heparan sulfate proteoglycan (HSPG) in host hepatocyte and bile acid receptor.